An observational study in Covid19, sponsored by Sykehuset Telemark. Active, not recruiting at 1 site in Norway. Open to participants aged 18 Years to 85 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-17.
Sponsored by Sykehuset Telemark · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 47 studies in COVID-19 with a site in Norway — 3 open to participants now, 7 under way, 1 of them phase 3. COVID-19 · Norway.
Among the 47 studies in COVID-19 with a site in Norway, this one is the 10th largest by planned enrollment of the 23 observational ones that give a count, is one of 25 that started in 2020, is one of 23 observational ones, and was the 15th registered.
7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.
Browse COVID-19 studies →3 of the 47 studies in COVID-19 with a site in Norway are open now. Recruiting first, the newest first:
University Hospital of North Norway · Sites in Norway
Ages 18–65
ANRS, Emerging Infectious Diseases · Sites in Norway, France, Italy
Ages 16+
University of Bergen · Sites in Norway
Ages 20–100
A study can be open while its sites in Norway have not opened yet or have stopped. Only those recruiting at a site in Norway →
Of the 356 COVID-19 studies recruiting now, 205 (58%) set no upper age limit and 84 (24%) stop at 75 or younger; 90 take children under 18; 135 take healthy volunteers.
This study: 18 Years to 85 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
47 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 5 · Phase 3 4 · Phase 4 1
First in 2020; this study’s year is marked. 25 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,200 is above the median of 268 across 3,209 observational studies indexed under COVID-19.
Median enrollment 302 across the 24 interventional studies, 860 across the 23 observational. Of the 32 that completed or were terminated, 1 (3%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 47 have an industry lead sponsor. The 10 most frequent:
Sykehuset Telemark is the lead sponsor of 33 studies on the registry; 6 are open to participants now.
Sykehuset Telemark has 1 study filed under COVID-19 — fewer than ten, so there is no comparison to draw.
2 of the studies in COVID-19 with a site in Norway that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04514003Sykehuset TelemarkThe Corona and COVID-19 Study in Telemark and Agder | 2026-12-31 |
| NCT05587894ANRS, Emerging Infectious DiseasesOPtimisation of Antiviral Therapy in Immunocompromised COVID-19 Patients: a Randomized Factorial Controlled Strategy Trial | 2026-12-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 47 studies in COVID-19 with a site in Norway, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Through SARS-CoV-2 IgG testing of PCR positive and negative cases the study will follow the COVID-19 immune response by monitoring the SARS-CoV-2 IgG antibody levels over a period of two years. Further, risk factors will be identified by the use of the test-negative design including population controls, allowing comparison of participants with positive and negative tests, and with population controls (triangulation). Special emphasis will be on high risk groups in general and on different occupational, environmental and socio-economic groups in particular. Finally, severity of illness, deaths and the use of health care during will be assessed using national register data from Telemark and Agder.
Objectives
The main objectives are:
The main exposures are (WP1-3):
Inhabitants of Agder and Telemark County in Norway fulfilling the inclusion criteria.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Antibody tests will be performed every 6 months for 2 years
Antibody tests will be performed at baseline
A large sample (n= 22500) from the general population will be included to assess risk factors. No blood sample will be collected for this group and the data needed is already collected.
SARS-CoV-2 IgG antibody level
Serum Levels of SARS-CoV-2 IgG antibody and the Development of these over a two years period
Time frame: 2020-2023
Risk factors for COVID-19
Different risk factors (age, sex, education, comorbidity, occupational and environmental exposure will be assessed
Time frame: 2020-2026
Plan to share: No
Started Jul 2020 (actual). Primary completion is estimated for Dec 2026, 77 months after the start.
Of 1,640 non-industry observational studies under COVID-19, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 30. This study's planned 77 months is above that.
Counting every sponsor, half of 1,774 studies reached it within 13 months; a quarter within 5 and three quarters within 29.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Sykehuset Telemark